What Caligan Partners LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1727492 · Filed Nov 16, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 8.1M |
| ±0% |
| $245.7M |
| 15% |
ABVXAbivax S.A. | 1.6M | ±0% | $154.3M | 9.4% |
PCVXVaxcyte, Inc. | 2.2M | ±0% | $124.5M | 7.6% |
EXELExelixis, Inc. | 1.6M | ±0% | $90.7M | 5.6% |
TNGXTango Therapeutics, Inc. | 2.5M | +0.0% | $62.4M | 3.8% |
ADMAAdma Biologics, Inc. | 5.9M | +2.6% | $58.9M | 3.6% |
IMCRImmunocore Holdings plc | 1.7M | +21.1% | $50.6M | 3.1% |
AVTXAvalo Therapeutics, Inc. | 3.3M | +3.3% | $50.1M | 3.1% |
LBRXLB Pharmaceuticals Inc | 1.5M | +5.0% | $49.6M | 3% |
VRDNViridian Therapeutics, Inc.DE | 2.2M | ±0% | $45.2M | 2.8% |
VORVor Biopharma Inc. | 1.9M | ±0% | $36.7M | 2.2% |
IVAInventiva S.A. | 9.2M | +12.5% | $33.9M | 2.1% |
IRDOpus Genetics, Inc. | 6M | −1.9% | $28.9M | 1.8% |
AURAAura Biosciences, Inc. | 4.6M | +6.8% | $28.8M | 1.8% |
ANIKAnika Therapeutics, Inc. | 1.4M | ±0% | $28.2M | 1.7% |
SABSSAB Biotherapeutics, Inc. | 8.7M | +9.7% | $27.7M | 1.7% |
SGMTSagimet Biosciences Inc. | 2.8M | +11.8% | $27.6M | 1.7% |
FTHFaeth Therapeutics, Inc. | 890.2K | +41.4% | $26.5M | 1.6% |
TYRATyra Biosciences, Inc. | 910.7K | +12.9% | $19.9M | 1.2% |
OBXObsidian Therapeutics, Inc. | 886.3K | New | $12.2M | 0.7% |
EPRXEupraxia Pharmaceuticals Inc. | 1.2M | New | $10.6M | 0.6% |
ARTVArtiva Biotherapeutics, Inc. | 1.5M | −14.7% | $10.5M | 0.6% |
VRCAVerrica Pharmaceuticals Inc. | 923.9K | ±0% | $4.4M | 0.3% |
TCGXTCGX Acquisition Corp. | 200K | New | $2.5M | 0.2% |
CLRBCellectar Biosciences, Inc. | 470K | ±0% | $864.8K | 0.1% |